Biopôle Lausanne’s Post

Only 3 weeks until the 24th BioEquity Europe in San Sebastian, Spain. Please register now -- before it sells out! Partnering is open, 130+ biotechs confirmed to present, only a few slots left on our pre-event networking excursions (first-come, first-served). ✅ Register: https://lnkd.in/gSxxhu7 ✳️ One area to highlight -> This year's agenda focuses on: How can #biotechs "rise above the noise" to attract the right investors, partners and talent? Recent additions to the faculty, include: ➢ Arjen Lemmen of argenx ➢ Arno de Wilde of EQT Group ➢ Caroline Gaynor of Lightstone Ventures ➢ Christina Takke of V-Bio Ventures ➢ Claire Brown of Oxford Science Enterprises ➢ Dmitry 'Dima' Kuzmin of 4BIO Capital ➢ Elise Peters of Syncona Limited ➢ Florent Gros of Earlybird Venture Capital ➢ Franck Le Deu of McKinsey & Company ➢ Frank Kalkbrenner of Boehringer Ingelheim ➢ Jason P. Hafler of Sanofi ➢ Joep Muijrers of Gilde Healthcare ➢ Jonathan Tobin of Brandon Capital ➢ Karen Wagner of Ysios Capital ➢ Ksenija Pavletic of JEITO ➢ Nerida Scott of Johnson & Johnson ➢ Nina Rawal of Trill Impact ➢ Paulo Fontoura of Roche ➢ Dr. Shanshan Xu of BioNTech SE ➢ Søren Møller of Novo Nordisk And many more... I hope you will join BioCentury and EBD Group at this destination event for #biotech CEOs and investors. No event has a larger concentration of VCs than BioEquity. Please DM me if you have any questions. See you soon in San Sebastian! #venturecapital #drugdevelopment #biopharma #BioEquityEurope

📊 Our 2023 preliminary results are now out. Last year marked a significant milestone for Eden Research as we launched our seed treatment Ecovelex™ and brought it and our existing products into new, compelling markets. We look forward to building on this momentum in 2024!   Key highlights from the update: 💰 £3.2 million full-year revenue, a 78% increase from FY22 🌾 Launch and first commercial sales of Ecovelex following temporary approval in Italy for the 2024 growing season 🍇 Expansion of approvals for Mevalone® in New Zealand, Italy, Colombia and Poland 🐛 Progress on the development of an insecticide formulation with promising field trial results and ongoing conversations with commercial partners 📈 Investment of fundraising proceeds into product development, registration and commercialisation workstreams to realise Eden Research’s potential 💸 Strong cash position of £7.4 million, up from £2 million at FY22 Learn more here: https://lnkd.in/ej-tFb9b

⭕ Round table during #Horizon4Poland 2023 - The largest matchmaking event in the R&D sector in Poland 📅 Coming on November 2️⃣ 1️⃣ st 📍 Fabryka Norblina 👆 We'll discuss about IHI program - including public private partnership perspective. An open discussion led by Magdalena Kulczycka,Ph.D., Director of Central European BioForum, and Magali Poinot Team Leader of the Governance Cell at Innovative Health Initiative (IHI), will help answer questions such as: ✅ What SMEs need from the IHI program?  ✅ What obstacles do they have when applying to programs?   ✅ What are the benefits for SMEs ?  ✅ How big pharma companies see the benefits from IHI programs - for them/ for the ecosystem?  ✅ How IHI programs can stimulate the biotech ecosystem ?  ✅ How IHI programs stimulate the European ecosystem on a global scale? Interested ❓ Join us during the event ➡ https://lnkd.in/dkbRP5Kv Anna Kacprzyk, Monika Ślęzak, Katarzyna Banyś, Igor Deryło #HoryzontEuropa, #science, #business, #cooperation

At the Asia Health & Life Sciences Innovation Summit, Jolene Ooi from our healthcare investment team participated in a panel discussion on global investment supporting the Asian life sciences industry with Chang Liu, Michael Chang, Wendy Wu Jie, Navjeewan Khosla, and Fong Ming Koh, Ph.D.. The discussion covered short and long-term opportunities, nuanced investment strategies to navigate ongoing gaps and challenges, and the importance of cross-regional collaboration in driving growth. 📈 We believe 🇸🇬 Singapore is poised to play an increasingly important role in the region's growth. It has contributed innovative IP, such as Hummingbird Bioscience's recent licensing deal with Endeavor Biomedicines in the US, and acts as a strategic hub to access regional markets, further signalling the region's growing potential. #EDBI #Lifesciences #Healthcare

Looking forward to connecting with Bio Companies at Bio Europe Spring to Dive into the compelling reasons why Puerto Rico stands out as a prime destination for Bio Pharma companies growth: - Puerto Rico Talent: Tap into a skilled and diverse workforce, fostering innovation and driving success. - Tax benefits: 1-4% fixed corporate tax rate on eligible income, among other financial incentives. - Part of the U.S.: Puerto Rico offers the same level of operational security, political stability and support, and protections available on the mainland.  - R&D Tax Credit: Up to 50% Tax Credit on qualified Research & Development Activities - Transferable & Sellable. - Innovation: Seamless integration into a thriving tech innovation R&D ecosystem. Last but not least ! Puerto Rico is “The Gateway to the Americas.” From here, you can access the North American, South American, and Caribbean markets with ease and stability under the Made in the USA seal See you soon Bio Europe !!!! #bioeuropespring #Bioconvention #Europe

Attention all healthcare investors! QIC is proud to introduce the Taiwan Healthcare Monthly Dose – a bespoke investment newsletter catering to those interested in the healthcare, biotech, pharma, and Medtech sectors. Each month, we will provide the latest market insights, updates on Taiwan and global news events, and our expert commentary. If there are specific topics or information you would like to see covered in our Monthly Dose, please don't hesitate to let us know. We are committed to delivering the content that matters most to you. Additionally, if you have any feedback or would like to subscribe to every issue of the Taiwan Healthcare Monthly Dose, please feel free to reach out to us! #QIC #Taiwan #BioTech #Healthcare #Newsletter #InvestmentInsights #TaiwanBusiness #MonthlyPublication #LaunchAlert 🚀📊  Kuan-Jan W. Peter Kurz

Achelous Partners is pleased to announce that we have continued our European expansion and have recently opened an office in Spain to be led by Prof. Sergi X. Trilla, MD, MBA. Prof. Trilla has extensive expertise in the life sciences industry and has developed strong client relationships over his 30-year career. Achelous Partners has completed numerous transactions across Europe, and Spain is a key growth market. Prof. Trilla’s involvement will significantly enhance our ability to serve our clients in Spain and across Europe, while also identifying new global opportunities, including Latin America.   Prof. Trilla joins Achelous Partners from trifermed, where he serves as Founder and President. With a focus on corporate strategy and business development, trifermed has been instrumental in transforming innovative ideas into market-ready solutions. Prof. Trilla’s leadership and strategic vision have been critical in orchestrating over 200 global strategic partnerships and driving substantial growth in the healthcare sector.   We look forward to Sergi’s contributions to our continued success. #LifeSciences #Biotechnology #Expansion #Spain #Europe #M&A

🇨🇭 Switzerland excels in life sciences, attracting global talent and capital. Top pharma, biotech, and medtech companies like Biogen, Organon, #Novartis, and #Roche thrive, alongside many smaller firms. This vibrant ecosystem fosters innovation and partnerships. Swiss life science: a global powerhouse - 1,400 manufacturers and service providers - 110 billion CHF in exports - 114,510 employees - 3,124 companies MedDevice/Digital Health: leading innovation Switzerland is a prime destination for MedDevice and digital health, boasting the highest number of medtech companies per resident in Europe. Key strengths include: Strong research and skilled workforce Supportive regulatory environment Access to capital and strategic partnerships Switzerland’s biotech powerhouse Driven by renowned academic institutions, proximity to biopharma, robust IP protection, and political stability, Switzerland offers an outstanding environment for health tech innovation. Discover more of the advantages of Switzerland for the future of health: https://lnkd.in/dRbTFcfg #LifeScience #DigitalHealth #Switzerland #MedTech

🇧🇪 Belgium, and particularly Wallonia have an ATMP ecosystem that is unique in Europe. BioWin, and its members, have been working for months on a strategic initiative focusing on advanced therapies; disruptive approaches that open up new fields in the history of medicine by enabling patients to be cured - and no longer just treated. The objective is to bring together large companies, SMEs, research centres, universities and hospitals to consolidate the entire value chain. 👉 Read more: https://lnkd.in/ek8TrCj4

ESG initiatives are increasingly prioritized by Asia Pacific medtech companies and their customers, according to a survey conducted jointly by Bain & Company and Asia Pacific Medical Technology Association (APACMed). The survey, which was completed in May and included 120 customers and over 800 employees and executives from medtech companies across six Asia Pacific markets found that more than 70% of medtech customers had already defined Environmental, social, and governance (ESG) strategies, 60% of medtech employees reported that their companies have established ESG ambitions and had set specific targets.